TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01914146

Intervention type: OTHER
Group type: OTHER
Intervention: Insulin
Description: Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.

Intervention type: OTHER
Group type: OTHER
Intervention: No Insulin
Description: Study session will occur prior to initiation of insulin therapy.
Study: NCT04028869

Intervention type: DRUG
Intervention: Glycyrrhizic acid preparation
Description: To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
Study: NCT00974467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After The Injury website
Description: Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual hospital care provided.
Study: NCT01927003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal digito-metacarpal flap
Description: The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
Study: NCT02669901

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Naloxone Auto-Injector
Description: Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
Study: NCT02728154

Intervention type: OTHER
Intervention: Blood Sample
Description: One tablespoon of blood will be drawn once during the study.

Intervention type: OTHER
Intervention: Blood Sample
Description: One tablespoon of blood will be drawn once during the study.
Study: NCT01552668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: Receive 200 mg of fidaxomicin twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive Placebo twice daily
Study: NCT01292317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of intravenous volume
Description: weight based intravenous application of volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral fluid application
Description: oral fluid application
Study: NCT03502642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
Study: NCT04909632

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC-MS) analysis
Description: The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
Study: NCT01823003

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 34 Gy in a single fraction
Description: 34 Gy in a single fraction in case of Distance to chest wall \> 1 cm, tumour size \< 2 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 54Gy 18Gy/fr. x 3 fractions
Description: 54Gy administered in 3 fractions of 18Gy in case of distance to chest wall \> 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy (12 x 5 fr.s)
Description: 50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy (7.5Gy x 8fr.)
Description: 60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
Study: NCT00365352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 600MG
Description: XP13512 600MG ONCE DAILY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 1200MG
Description: XP13512 1200MG ONCE DAILY

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO ONCE DAILY
Study: NCT01568008

Intervention type: DRUG
Intervention: Bimatoprost 0.01% ophthalmic solution
Description: Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
Study: NCT02728154

Intervention type: OTHER
Intervention: Blood Sample
Description: One tablespoon of blood will be drawn once during the study.

Intervention type: OTHER
Intervention: Stool Sample
Description: One stool sample will be collected.

Intervention type: OTHER
Intervention: Stool Sample
Description: One stool sample will be collected.

Intervention type: OTHER
Intervention: Stool Sample
Description: One stool sample will be collected.
Study: NCT02202993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibefradil with Radiation
Description: Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy.
Study: NCT03562611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen axetil administration during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine and Flurbiprofen Axetil
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study: NCT02693171

Intervention type: DRUG
Intervention: Dinutuximab
Description: Unituxin was administered along with cytokines according to the prescribing information
Study: NCT03342027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: medication for smoking cessation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: medication for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively smoke free
Description: an 8 session, tailored behavioral intervention for treating tobacco dependence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively smoke free
Description: an 8 session, tailored behavioral intervention for treating tobacco dependence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief advice to quit smoking
Description: Standardized brief advice to quit smoking (standard of care)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brief advice to quit smoking
Description: Standardized brief advice to quit smoking (standard of care)
Study: NCT03244540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB (quadratus lumborum block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimuplex Ultra 360 needle
Description: ultrasound-guided needle will be used for QLB and TAP and regional blocks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimuplex Ultra 360 needle
Description: ultrasound-guided needle will be used for QLB and TAP and regional blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study: NCT04032041

Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.

Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.

Intervention type: DEVICE
Intervention: Caliper
Description: Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.

Intervention type: DEVICE
Intervention: Caliper
Description: Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.
Study: NCT03244540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study: NCT02411656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03362476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based alcohol reduction intervention
Description: Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief clinician-delivered MET
Description: Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief clinician-delivered MET
Description: Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
Study: NCT03164148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-REX TRI00A
Description: Case management consists of confirmation of hospital visit date, checking the adverse effect
Study: NCT03244540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid anesthesia
Description: subarachnoid anesthesia for each patients participating in the study with pencil point needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid anesthesia
Description: subarachnoid anesthesia for each patients participating in the study with pencil point needle
Study: NCT02599870

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NeuroIDgenetix Test Panel
Description: The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
Study: NCT04249362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Study: NCT03139383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dextrose solution
Description: The patients received 5%D/N/2 during surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: The patients received NSS during surgery
Study: NCT02764788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific auriculotherapy
Description: Specific auriculotherapy with needles
Study: NCT03244540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid anesthesia
Description: subarachnoid anesthesia for each patients participating in the study with pencil point needle
Study: NCT01834443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct current galvanic vestibular stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct current galvanic vestibular stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct current galvanic vestibular stimulation
Study: NCT04540107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT00884754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope rigid stylet
Description: Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope rigid stylet
Description: Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
Study: NCT01087996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto-hMSCs
Description: Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
Study: NCT03244540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA (patient controlled analgesia)
Description: All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
Study: NCT02411838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI\>28 will follow a regimen of fasting for three days per week.
Study: NCT02500459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
Study: NCT00903734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride (Tarceva)
Description: Dose of 150 mg daily by mouth.
Study: NCT02764788

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-specific auriculotherapy
Description: non-specific auriculotherapy with needles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: seed auriculotherapy
Description: non-specific auriculotherapy with seeds
Study: NCT03916601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous